| 1601 |
Bone Marrow |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Belgium
|
50 |
| 1602 |
Bone Marrow |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
France
|
31 |
| 1603 |
Bone Marrow |
Allogeneic
|
Chronic myelomonocytic leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Italy
|
64 |
| 1604 |
Bone Marrow |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy
|
France
|
10 |
| 1605 |
Bone Marrow |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
12 |
| 1606 |
Bone Marrow |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
4 |
| 1607 |
Bone Marrow |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Canada
|
8 |
| 1608 |
Bone Marrow |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
17 |
| 1609 |
Bone Marrow |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
8 |
| 1610 |
Bone Marrow |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
67 |
| 1611 |
Bone Marrow |
Allogeneic
|
Hodgkins Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
United Kingdom
|
36 |
| 1612 |
Bone Marrow |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
72 |
| 1613 |
Bone Marrow |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
9 |
| 1614 |
Bone Marrow |
Allogeneic
|
Chronic Granulomatous Disease
|
Hematology
|
2024
|
Standard Therapy
|
USA
|
3 |
| 1615 |
Apheresis |
Allogeneic
|
A- Thalassemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
11 |
| 1616 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
13 |
| 1617 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
21 |
| 1618 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
22 |
| 1619 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
38 |
| 1620 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
41 |
| 1621 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
44 |
| 1622 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
44 |
| 1623 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
48 |
| 1624 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
50 |
| 1625 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
50 |
| 1626 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
55 |
| 1627 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
59 |
| 1628 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
60 |
| 1629 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
63 |
| 1630 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
44 |
| 1631 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
59 |
| 1632 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
51 |
| 1633 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
34 |
| 1634 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
1 |
| 1635 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
10 |
| 1636 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
20 |
| 1637 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
25 |
| 1638 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
26 |
| 1639 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
28 |
| 1640 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
34 |
| 1641 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
35 |
| 1642 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
37 |
| 1643 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
38 |
| 1644 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
38 |
| 1645 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
40 |
| 1646 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
41 |
| 1647 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
43 |
| 1648 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
51 |
| 1649 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
51 |
| 1650 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
51 |
| 1651 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
59 |
| 1652 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
59 |
| 1653 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1654 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1655 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1656 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
61 |
| 1657 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
61 |
| 1658 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1659 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1660 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
64 |
| 1661 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
65 |
| 1662 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
66 |
| 1663 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
67 |
| 1664 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
67 |
| 1665 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
68 |
| 1666 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
69 |
| 1667 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
69 |
| 1668 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
69 |
| 1669 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
69 |
| 1670 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
69 |
| 1671 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
70 |
| 1672 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
70 |
| 1673 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
72 |
| 1674 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
73 |
| 1675 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
77 |
| 1676 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
59 |
| 1677 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
66 |
| 1678 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
58 |
| 1679 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
54 |
| 1680 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
29 |
| 1681 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
64 |
| 1682 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
27 |
| 1683 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1684 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
63 |
| 1685 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
50 |
| 1686 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1687 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
30 |
| 1688 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
68 |
| 1689 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
77 |
| 1690 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1691 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
47 |
| 1692 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1693 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
65 |
| 1694 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
64 |
| 1695 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
61 |
| 1696 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
64 |
| 1697 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia- Core-Binding Factor
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
68 |
| 1698 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia, Post Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
63 |
| 1699 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
36 |
| 1700 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
46 |